RenovoRx (NASDAQ:RNXT) Posts Earnings Results, Hits Expectations

RenovoRx (NASDAQ:RNXT) announced its earnings results on Monday. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08), FiscalAI reports. The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.42 million. RenovoRx had a negative net margin of 1,196.66% and a negative return on equity of 122.19%. During the same period in the previous year, the business earned ($0.40) earnings per share.

Here are the key takeaways from RenovoRx’s conference call:

• RenovoRx achieved initial commercial traction with $1.1M in 2025 revenue, reported Q4 revenue of $238k, has 12 active U.S. centers (33-center near‑term pipeline) and is targeting ~36 active sites by year‑end 2026 with company guidance that 2026 revenue should be roughly $3M–$4M.
• The company strengthened its balance sheet with an oversubscribed private placement closing on March 23, 2026 that raised ~$10M gross, supplementing ~$7M cash at year‑end 2025 to fund commercial scale‑up and TIGeR‑PaC completion.
• The Phase III TIGeR‑PaC trial is nearing its enrollment target (104 of 114 randomized as of March 24, 2026) with 72 of 86 events observed and final data expected in 2027, representing a material clinical catalyst if positive.
• Near‑term revenue remains lumpy and scale‑constrained (quarterly results swing based on a small number of active centers and timing of first patient treatments), while R&D and SG&A run rates and the need to convert trial sites to commercial use pose execution and dilution risks if commercial adoption is slower than planned.

RenovoRx Stock Down 1.9%

RenovoRx stock opened at $1.05 on Tuesday. The firm has a fifty day simple moving average of $0.95 and a two-hundred day simple moving average of $1.01. RenovoRx has a twelve month low of $0.70 and a twelve month high of $1.45. The company has a market capitalization of $38.48 million, a PE ratio of -2.92 and a beta of 1.34.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Wall Street Zen raised RenovoRx from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of RenovoRx in a research report on Monday, December 29th. JonesTrading raised RenovoRx to a “strong-buy” rating in a report on Thursday, January 29th. Finally, Ascendiant Capital Markets boosted their target price on RenovoRx from $12.50 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. XTX Topco Ltd lifted its stake in shares of RenovoRx by 58.6% in the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock valued at $42,000 after acquiring an additional 18,525 shares during the last quarter. Geode Capital Management LLC grew its position in RenovoRx by 9.9% during the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock worth $467,000 after acquiring an additional 31,730 shares during the last quarter. Bleichroeder LP increased its stake in RenovoRx by 11.4% in the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock worth $504,000 after purchasing an additional 61,379 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new position in RenovoRx in the 2nd quarter worth approximately $98,000. Finally, Citadel Advisors LLC bought a new stake in RenovoRx in the third quarter valued at approximately $154,000. Hedge funds and other institutional investors own 3.10% of the company’s stock.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.